Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Napo Pharmaceuticals Inc.

Division of Jaguar Health Inc.
www.napopharma.com

Latest From Napo Pharmaceuticals Inc.

Deal Watch: Amazon Moves Into Rx Services With Acquisition Of PillPack

Celgene makes play into RNA-expression correction via neuroscience partnership and equity investment with Skyhawk. Novartis’ Sandoz agreed to commercialize Adamis’ Symjepi, a competitor to EpiPen, in the US.

Deals Commercial

Vanda's Licenses CFTR Modulators From UCSF, But Not For Cystic Fibrosis

Intellectual property licensed from UCSF focuses on non-mutated, wild-type CFTR activators and inhibitors, thought to offer potential in ophthalmic, renal and gastrointestinal indications.

Commercial Business Strategies

Record-breaking: Scrip analyzes 2013's new product launches

A host of quadrivalent flu vaccines helped boost the number of new active substances (NASs) launched in their first markets worldwide in 2013 to a record high for this century so far.

Metabolic Disorders Gastrointestinal

STOCKWATCH: Echoes from the last biotech bubble

Broad stock markets seem to be schizophrenic; flitting between the worry of a tapering of quantitative easing in the US, a credit crunch in China, and then just ignoring all those issues. The US biotechnology sector mirrors this duality but for different reasons with the NASDAQ Biotech index (NBI) being off almost 7% from its mid-May peak, but IPOs and secondary offerings still flood the market.

Cardiovascular Orthopedics
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Pharmaceuticals
  • Therapeutic Areas
  • Gastrointestinal
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Jaguar Health Inc.
  • Senior Management
  • Lisa A Conte, CEO
    Karen Wright, CFO
    Katie MacFarlane, SVP, Commercial Dev.
    Brian Zorn, SVP, Mktg. & Sales
  • Contact Info
  • Napo Pharmaceuticals Inc.
    Phone: (415) 963-9938
    201 Mission St., Ste. 2375
    San Francisco, CA 94105
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register